Landmark study: malaria gets less than 1% of global health R&D investment

The new report focuses on three questions: Who invested in R&D, who received funding, and how the funding is distributed.

30 Oct 2005

The Malaria R&D Alliance, an international coalition of malaria research groups, released a new study on 30 October 2005, Malaria Research & Development: An Assessment of Global Investment which reports that global funding in 2004 for malaria R&D totaled just $323 million - far short of the amount needed.

The last such similar study was completed in 1996 by the Wellcome Trust, and was based on 1993 data. Compared with this previous benchmark, and adjusted for inflation, the current study shows an annual average increase in funding of about 8 percent since 1993.

The 52-page landmark study analyzed funding in the following R&D categories:

  • antimalarial drug discovery and development,
  • vaccine development and trials,
  • basic research,
  • implementation research,
  • vector control research, and
  • development of malaria diagnostics.

The new report focused on three questions: Who invested in R&D, who received funding, and how the funding is distributed.

The study found that funding for malaria R&D activities was derived from only a few donors. The top two funders - the U.S. National Institute of Allergies and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation - accounted for nearly half of all funding in 2004. The top 12 sources of funding accounted for 88 percent of the total investment.

Attachments